HomeCompareRE vs MRK

RE vs MRK: Dividend Comparison 2026

RE yields 1.88% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $25.9K in total portfolio value
10 years
RE
RE
● Live price
1.88%
Share price
$351.28
Annual div
$6.60
5Y div CAGR
24%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.8K
Annual income
$2,339.60
Full RE calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RE vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RE
Annual income on $10K today (after 15% tax)
$159.70/yr
After 10yr DRIP, annual income (after tax)
$1,988.66/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $6,339.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RE + MRK for your $10,000?

RE: 50%MRK: 50%
100% MRK50/50100% RE
Portfolio after 10yr
$43.8K
Annual income
$6,068.87/yr
Blended yield
13.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RE
Analyst Ratings
11
Buy
9
Hold
Consensus: Buy
Price Target
$359.75
+2.4% upside vs current
Range: $344.00 — $385.00
Altman Z
1.0
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RE buys
0
MRK buys
0
No recent congressional trades found for RE or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREMRK
Forward yield1.88%2.76%
Annual dividend / share$6.60$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24%32.7%
Portfolio after 10y$30.8K$56.8K
Annual income after 10y$2,339.60$9,798.13
Total dividends collected$9.3K$28.9K
Payment frequencyquarterlyquarterly
SectorFinancialsHealthcare
Analyst consensusBuyBuy
Analyst price target$359.75$128.54

Year-by-year: RE vs MRK ($10,000, DRIP)

YearRE PortfolioRE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,933$232.98$11,206$366.19$273.00MRK
2$11,993$295.18$12,650$502.35$657.00MRK
3$13,208$375.26$14,407$694.19$1.2KMRK
4$14,612$478.93$16,585$967.82$2.0KMRK
5$16,249$614.00$19,342$1,363.89$3.1KMRK
6$18,177$791.26$22,913$1,947.19$4.7KMRK
7$20,475$1,025.81$27,662$2,823.89$7.2KMRK
8$23,248$1,339.10$34,159$4,173.35$10.9KMRK
9$26,637$1,761.97$43,337$6,308.80$16.7KMRK
10$30,841$2,339.60$56,776$9,798.13$25.9KMRK

RE vs MRK: Complete Analysis 2026

REFinancials

Everest Re Group, Ltd., through its subsidiaries, provides reinsurance and insurance products in the United States, Bermuda, and internationally. The company operates through Reinsurance Operations and Insurance Operations segments. The Reinsurance Operations segment writes property and casualty reinsurance; and specialty lines of business through reinsurance brokers, as well as directly with ceding companies in the United States, Bermuda, Ireland, Canada, Singapore, Switzerland, and the United Kingdom. The Insurance Operations segment writes property and casualty insurance directly, as well as through brokers, surplus lines brokers, and general agents in Bermuda, Canada, Europe, South America, Canada, Chile, the United Kingdom, Ireland, and the Netherlands. The company also provides treaty and facultative reinsurance products; admitted and non-admitted insurance products; and property and casualty reinsurance and insurance coverages, including marine, aviation, surety, errors and omissions liability, directors' and officers' liability, medical malpractice, mortgage reinsurance, other specialty lines, accident and health, and workers' compensation products. In addition, it offers commercial property and casualty insurance products through wholesale and retail brokers, surplus lines brokers, and program administrators. Everest Re Group, Ltd. was founded in 1973 and is headquartered in Hamilton, Bermuda.

Full RE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RE vs SCHDRE vs JEPIRE vs ORE vs KORE vs MAINRE vs JNJRE vs ABBVRE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.